Literature DB >> 28321812

Optimizing Radiotherapy with Immunotherapeutic Approaches.

Jonathan E Schoenhals1, Tijana Skrepnik2, Ugur Selek3,4, Maria A Cortez1, Ailin Li1,5, James W Welsh6.   

Abstract

Several factors must be considered to successfully integrate immunotherapy with radiation into clinical practice. One such factor is that concepts arising from preclinical work must be tested in combination with radiation in preclinical models to better understand how combination therapy will work in patients; examples include checkpoint inhibitors, tumor growth factor-beta (TGF-β) inhibitors, and natural killer (NK) cell therapy. Also, many radiation fields and fractionation schedules typically used in radiation therapy had been standardized before the introduction of advanced techniques for radiation planning and delivery that account for changes in tumor size, location, and motion during treatment, as well as uncertainties introduced by variations in patient setup between treatment fractions. As a result, radiation therapy may involve the use of large treatment volumes, often encompassing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized to combine with immunotherapy.

Entities:  

Keywords:  CD8+ T-cell; CTLA4; Clinical trial; Immunotherapy; PD1; Radiation; SABR; SBRT; TGF-β

Mesh:

Substances:

Year:  2017        PMID: 28321812     DOI: 10.1007/978-3-319-53156-4_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.

Authors:  Anthony L Schwartz; Pulak R Nath; Michael Allgauer; Elizabeth C Lessey-Morillon; John M Sipes; Lisa A Ridnour; Y Maurice Morillon Ii; Zhiya Yu; Nicholas P Restifo; David D Roberts
Journal:  Cancer Immunol Immunother       Date:  2019-10-18       Impact factor: 6.968

Review 2.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Authors:  Yu Chen; Min Gao; Zhaoqin Huang; Jinming Yu; Xiangjiao Meng
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

Review 3.  Harnessing the potential of multimodal radiotherapy in prostate cancer.

Authors:  Yiannis Philippou; Hanna Sjoberg; Alastair D Lamb; Philip Camilleri; Richard J Bryant
Journal:  Nat Rev Urol       Date:  2020-05-01       Impact factor: 14.432

Review 4.  Toxicity of radiation and immunotherapy combinations.

Authors:  Vivek Verma; Taylor R Cushman; Chad Tang; James W Welsh
Journal:  Adv Radiat Oncol       Date:  2018-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.